Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Inhibitor Therapeutics, Inc.HPPI · Entity 7783 | 10% owner | June 30, 2017 | July 12, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Inhibitor Therapeutics, Inc.
Report date June 30, 2017 · Filed July 12, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $.0001 par value per shareSEC Table I · non-derivative | Direct | 79,627,069 |
Reported balance
After 2017-06-30 transaction · row 1
1 source rowRow 1 · 2017-06-30 · Sale · Disposed 2,500,000 · Balance 79,627,069 F1: On June 30, 2017, the Reporting Person sold 2,500,000 shares of restricted common stock in a private transaction to an unaffiliated third party for a total purchase price of $500,000. |
Filing footnotes · ownership attribution and instrument terms
F1: On June 30, 2017, the Reporting Person sold 2,500,000 shares of restricted common stock in a private transaction to an unaffiliated third party for a total purchase price of $500,000.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 30, 2017 Filed Jul 12, 2017 20:05 UTC | Inhibitor Therapeutics, Inc. HPPI · Entity 7783 | SaleCommon Stock, $.0001 par value per share | 2,500,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-17-018211 · doc4.xml · nonDerivative · entry 1 HedgePath, LLC · CIK 0001584617 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,627,069 F1 · kind: On June 30, 2017, the Reporting Person sold 2,500,000 shares of restricted common stock in a private transaction to an unaffiliated third party for a total purchase price of $500,000. F1 · price: On June 30, 2017, the Reporting Person sold 2,500,000 shares of restricted common stock in a private transaction to an unaffiliated third party for a total purchase price of $500,000. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.